7 May 2020

Artificial Intelligence Expert Neil Sahota Joins Evoke Neuroscience Executive Advisory Board

by Evoke

NEWPORT BEACH, CA, USA, May 7, 2020 /EINPresswire.com/ — Evoke Neuroscience announced today that IBM Master Inventor,...

NEWPORT BEACH, CA, USA, May 7, 2020 /EINPresswire.com/ — Evoke Neuroscience announced today that IBM Master Inventor, United Nations Artificial Intelligence (AI) Subject Matter Expert, and UC Irvine Professor Neil Sahota has joined the company’s executive advisory board. For the past 20 years, Neil has worked with Global Fortune 500 companies and world government leaders to foster innovation and develop next-generation products and solutions powered by AI.

“Neil Sahota brings a wealth of knowledge, expertise, and strategic relationships that will propel us forward in our mission to reduce the number of people unnecessarily living with cognitive impairment,” said Marinela Gombosev, CEO of Evoke Neuroscience. “His expertise and global perspective are a great fit for where we are headed, and we are grateful to have his guidance as we integrate AI into the eVox platform.”

The eVox^® Brain Health System is 510(k) cleared to collect neurophysiology data that primary and specialty care physicians use to aid in diagnosis of cognitive disorders.

“Data is the fuel for AI, and Evoke has generated a cross-sectional database of over 58,000 computational EEG brain scans. This means Evoke has an exceptional vantage point to develop insights into EEG data interpretation that can be useful in novel diagnostic approaches,” said Neil Sahota. “I’m excited to be a part of Evoke Neuroscience and look forward to helping them develop successful strategies that leverage their unique data set to advance brain health measurement and diagnosis in clinical settings.”

Evoke Neuroscience is currently conducting an IRB approved study to develop an AI framework capable of diagnosing mild cognitive impairment (MCI) and Alzheimer’s disease (AD) in collaboration with the Pacific Neuroscience Institute Brain Health Center, an outpatient clinic of the Providence Saint John’s Health Center in Santa Monica, CA. Although currently no cure exists for Alzheimer’s, one in three cases of dementia could be prevented by addressing various lifestyle factors early. The AI framework will provide rapid, sensitive, and specific diagnosis of MCI and AD in a primary care setting, thereby accelerating next-level care in disease detection and treatment planning.

The use of this technology extends beyond neurodegenerative cognitive impairment, and can also help identify mental health disorders. In the midst of the global COVID-19 pandemic, feelings of anxiety and isolation are mounting. “COVID-19 has put a lot of stress on all of us,” Sahota notes. “We continue to witness the far-reaching social and economic impacts of COVID-19, and there’s a real concern that many people will suffer from post-traumatic stress syndrome (PTSD), alcoholism, or depression. Spending 10 minutes on Evoke’s mental health screeners may help physicians recognize signs of mental health distress in their patients, and give them the opportunity to prevent distress from turning into a disorder.” This month, Evoke launched its mental health screener program, provided free of charge to its current customers in time for May 2020 Mental Health Month.

About Neil Sahota:
Neil Sahota (www.neilsahota.com) is a futurist and leading expert on Artificial Intelligence (AI) and other next-generation technologies. He is the author of Own the AI Revolution (McGraw Hill) and works with the United Nations on the AI for Good initiative. Sahota is also an IBM Master Inventor, former leader of the IBM Watson Group and professor at the University of California/Irvine. His work spans multiple industries, including legal services, healthcare, life sciences, retail, travel, transportation, energy, utilities, automotive, telecommunications, media, and government.

About Evoke Neuroscience:
Evoke Neuroscience (www.evokeneuroscience.com) was formed in 2009 with the mission to improve diagnosis and treatment of cognitive disorders with objective, clinically meaningful, and easy-to-use products. Primary and specialty care physicians can use eVox^® to acquire objective and stable biomarkers of brain function in-office via a non-invasive procedure, in order to aid in the diagnosis of cognitive and mental disorders. Doctors should use their professional judgment in determining when the eVox^® System is appropriate to aid in diagnosis.

8 Nov 2019

Evoke Neuroscience aims to develop Artificial Intelligence biomarker for Alzheimer’s disease diagnosis

by Evoke

NEW YORK, NY, USA, November 8, 2019 /EINPresswire.com/ — Evoke Neuroscience, a medical device company developing and...

NEW YORK, NY, USA, November 8, 2019 /EINPresswire.com/ — Evoke Neuroscience, a medical device company developing and commercializing technologies to aid in diagnosis of cognitive disorders, announced today initial enrollment of subjects participating in an IRB approved study to develop an Artificial Intelligence (AI) biomarker of mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Conducted at the Pacific Neuroscience Institute Brain Health Center (PBHC), an outpatient clinic of the Providence Saint John’s Health Center in Santa Monica, CA, this study is utilizing Evoke’s flagship medical device, the eVox® System.

The eVox System is commercially available and used by primary and specialty care physicians to aid in diagnosis of memory loss and other cognitive disorders such as Alzheimer’s disease. In the ongoing study, eVox will be used to collect computational electroencephalography (EEG) and event-related potentials (ERP) metrics for 300 patients with cognitive impairment. Data from these patients will be used together with Evoke’s existing database of over 55,000 standardized patient brain scans in order to train a novel end-to-end machine learning algorithm and develop a diagnostic digital signature of AD. The resulting AI biomarker is intended to provide rapid, sensitive, and specific diagnosis of MCI and AD in a primary care setting, thereby accelerating next-level care in disease detection and treatment planning.

“Alzheimer’s represents one of the most important public health concerns to affect us in the coming decades,” explains Dr. David Merrill, MD, PhD, PBHC director and geriatric psychiatrist, and study co-Principle Investigator. “Although currently no cure exists for Alzheimer’s, one in three cases of dementia could be prevented by addressing various lifestyle factors. But the key to prevention is recognizing brain changes related to cognitive decline as early as possible so physicians have adequate time to implement successful interventions.”

As the size and proportion of the U.S. population age 65 and older continue to increase, the number of Americans with Alzheimer’s or other dementias is anticipated to grow from 55 million in 2019 to 88 million by 2050. Delaying symptom onset by as little as 1 year could potentially lower AD prevalence by more than 9 million cases over the next 40 years. Thus, there is a need for sensitive and specific diagnostic tools to facilitate the early recognition of individuals at risk of dementia, who potentially can benefit from preventive interventions capable of postponing or avoiding the onset of this severe and disabling cognitive disorder.

“Our goal is to eradicate Alzheimer’s disease, and the first step towards that goal is establishing a precise diagnostic algorithm for AD detection,” said Dr. Morgan Ingemanson, PhD, Director of Medical Affairs at Evoke Neuroscience and study co-Principle Investigator. “We are thrilled to have begun data collection on what we anticipate to be a pivotal study in the AD digital diagnostics space. This milestone represents our continued commitment to providing the clinical community with critical tools to help diagnose patients with cognitive decline, and we are incredibly optimistic about pairing patient data collected at PBHC together with our vast existing EEG database in order to develop an AD digital signature. It has the potential to revolutionize the current gold standard in Alzheimer’s diagnosis.”

About Pacific Brain Health Center
Pacific Neuroscience Institute Brain Health Center (PBHC, www.pacificbrainhealth.org) is an outpatient clinic of the Providence Saint John’s Health Center in Santa Monica, CA specifically focused on the diagnosis and treatment of patients with subjective cognitive impairments (SCI), mild cognitive impairment (MCI), Alzheimer’s disease (AD) and other dementias. The PBHC has assembled a highly experienced team of full-time specialists, all previously esteemed researchers and clinicians from UCLA and UCSD specializing in neurology, psychiatry, cognitive psychology, neuroscience and geriatric medicine.

About Evoke Neuroscience:
Evoke Neuroscience (www.evokeneuroscience.com) was formed in 2009 with the mission to improve diagnosis and treatment of cognitive disorders with objective, clinically meaningful and easy-to-use products. Primary and specialty care physicians can use eVox® to acquire objective and stable biomarkers of brain function in-office via a non-invasive procedure, in order to aid in the diagnosis of cognitive and mental disorders. Doctors should use their professional judgment in determining when the eVox® System is appropriate to aid in diagnosis.

Evoke News

Catch up on the latest from Evoke

8 Sep 2021

by Evoke Neuroscience

Evoke Neuroscience Enters Co-Marketing Agreement with Thought Technology

NEW YORK CITY, NY, USA, September 8, 2021 /EINPresswire.com/ — Founded in 2009, Evoke Neuroscience...

NEW YORK CITY, NY, USA, September 8, 2021 /EINPresswire.com/ — Founded in 2009, Evoke Neuroscience is on a mission to use brain health scans to reduce the number of people living with treatable cognitive impairment. To further this goal, Evoke Neuroscience has partnered with Thought Technology, a leading manufacturer of psychophysiological monitoring equipment designed to help individuals understand and improve their physiological processes. Evoke Neuroscience is confident that its partnership with Thought Technology will improve patient outcomes and enable clinicians to extend the scope of their practices.

Memory loss is often underdiagnosed, misdiagnosed, or diagnosed too late. Evoke Neuroscience wants to change that. FDA 510(k) approved to aid in diagnosis, Evoke’s eVox® System measures brain-based biomarkers through a non-invasive assessment that can be performed in a clinician’s office. The eVox® System assesses brain health and processing speed via quantitative EEG and event-related potentials (ERPs). Along with patient history and other clinical observations, the eVox® Report can assist physicians in detecting cognitive impairment early and performing a differential diagnosis. The eVox® System is trusted by the Premier Healthcare Alliance, the Department of Veterans Affairs, and leading clinicians across the country.

Once a physician has identified their client’s unique needs through the eVox® Assessment, they can use Thought Technology’s trusted instrumentation to provide their patients with appropriate biofeedback or neurofeedback training. Detection, diagnosis, and support for cognitive impairment can, therefore, remain under the same roof – streamlining and enhancing the care process for patients and providers alike.

“Starting with a functional assessment using EEG, ERPs, and ECG permits a better understanding of patient symptoms and alternative treatment options,” said Dave Hagedorn, PhD, CEO of Evoke Neuroscience. “Partnering with Thought Technology serves our core mission to assist medical providers and government clients with the highest quality applied neuroscience tools in the industry.”

About Thought Technology, Ltd.
www.thoughttechnology.com

A pioneer in the field with over 45 years of experience, Thought Technology manufactures biofeedback, neurofeedback, and psychophysiological instruments to help people perform better physically and mentally. Today, Thought Technology’s products are used by clinicians, trainers, and researchers in over 85 countries.

About Evoke Neuroscience
For over a decade, Evoke Neuroscience has assisted physicians in providing early detection, faster treatment, and better lives to individuals with cognitive impairment. Evoke’s eVox® System helps clinicians recognize signs of cognitive impairment and identify the causes while there’s still time for treatment. In the past 10 years, Evoke’s partners have completed over 60,000 eVox® Assessments and collected over 200 billion brain health data points.

18 Sep 2019

by Evoke Neuroscience

Allied : Signs Letter of Intent with Evoke Neurosciences to Partner on the Analysis and Treatment of PTSD Patients

Allied Corp. (OTC Pink: ALID) (“Allied”), an international medical cannabis production company...

Allied Corp. (OTC Pink: ALID) (“Allied”), an international medical cannabis production company focused on creating and providing targeted cannabinoid health solutions, is pleased to announce its signing of a Letter Of Intent (“the LOI”) with Evoke Neurosciences (“Evoke”). Evoke’s eVox System generates an objective and automated report for clinicians and researchers to use as a baseline and to aid diagnosis and facilitate treatment planning for patients living with PTSD. Under the LOI, Allied would employ Evoke’s eVox System to assess the function of the Central and Autonomic Nervous System via EEG, ECG, and Event-Related Potentials (ERPs).

This data is collected via an easy-to-use, FDA-cleared, class 2 medical device that acquires patient data non-invasively in a clinical setting. With the eVox System, clinicians can establish a baseline of the patient’s brain function, monitor treatment effects and measure changes in brain function. Additionally, clinicians who use the eVox System have found that the objective data facilitates a greater buy-in from patients that can lead to increased patient adherence.

This mutually beneficial partnership between Allied and Evoke would be characterized by the following:

Evoke could support Allied’s existing and planned clinical trials by providing pre- and post- treatment measurements of patients’ cognitive functions. The eVox system could be readily deployed for these efforts and Evoke would be able to train staff on how to operate the device to collect data. The eVox System reports would be automatically generated and be accessible via a web portal. Depending on the study objectives, Evoke could develop a custom report. Allied Corp. would publish the results of the clinical trial to further substantiate the utility of EEG, ERPs, and ECG as vital measures (biomarkers).
Allied would develop a commercial package that pairs its therapy products with a pre- and post- treatment eVox assessment. This would help Allied differentiate its products to a clinician target market.
Allied and Evoke could work together to expand their existing marketing efforts with respect to Veterans, PTSD patients and new markets (e.g. Pain management). Evoke has the capability to provide objective measures of PTSD and chronic pain that could be customized for the specific application.
“We are extremely excited to partner with Evoke,” said Calum Hughes, CEO of Allied Corp. “This partnership not only facilitates a greater understanding of PTSD, but it also accelerates the path to treatment for veterans and first responders. We believe that by utilizing the eVox technology, we would accumulate essential data that will aid in further developing a better therapeutic solution.”

About Evoke Neuroscience:
Evoke Neuroscience (www.evokeneuroscience.com) was formed in 2009 with the mission to improve diagnosis and treatment of cognitive disorders with objective, clinically meaningful and easy-to-use products. Primary and specialty care physicians can use eVox® to acquire objective and stable biomarkers of brain function in-office via a non-invasive procedure, in order to aid in the diagnosis of cognitive and mental disorders. Doctors should use their professional judgment in determining when the eVox® System is appropriate to aid in diagnosis.

10 Sep 2019

by Evoke Neuroscience

Evoke Neuroscience takes on TBI, PTSD with the US Air Force

NEW YORK CITY, NY, USA, September 10, 2019 /EINPresswire.com/ — Evoke Neuroscience has been awarded...

NEW YORK CITY, NY, USA, September 10, 2019 /EINPresswire.com/ — Evoke Neuroscience has been awarded a working contract by the United States Air Force (USAF) for its diagnostic device, the eVox® System.

The contract is part of the USAF Small Business Innovation Research (SBIR) Phase I program that provides the framework for a fully integrated solution with Air Force constituents.

Timely diagnosis of military personnel with mTBI, stress-related conditions, PTSD, and related memory loss or cognitive symptoms is critical and brain-based biomarkers can help. The eVox® System is a medical device that acquires computational EEG/ERP biomarkers to provide automated, objective, and non-invasive measurements of brain function to aid in diagnosis. The contract award enables the Air Force to acquire and evaluate eVox specifically for use cases with USAF stakeholders.

Air Force Research Lab (AFRL) and AFWERX have partnered to streamline the SBIR process in an attempt to speed up the experience, broaden the pool of potential applicants, and decrease bureaucratic overhead. Beginning in SBIR 18.2, and now in 19.2, the Air Force has begun offering ‘Special’ SBIR topics that are faster, leaner and open to a broader range of innovations.

“For the last 5 years, eVox has been used to support the mental health and medical care of U.S. Military personnel,” explains Marinela Gombosev, Evoke Neuroscience CEO. “Through this AFWERX SBIR Phase I contract award, we look forward to expanding access to objective biomarkers of brain function to Air Force service members who are deserving of the best available tools and medical care.”

At the conclusion of Phase I, Evoke will present a plan to deploy its technology -identifying USAF opportunities with the most critical need and highest potential benefit -for a subsequent AFWERX SBIR Phase II contract award.

This contract award expands upon Evoke Neuroscience’s government contract portfolio which includes a Veterans Health Administration Contract for the eVox® System (#36F79718D0348), that enables the VA and other federal organizations to purchase the eVox System at pre-approved pricing via the Veterans Administration’s FSS Contract, via GSA Advantage, or GSA eBUY.

About Evoke Neuroscience:
Evoke Neuroscience (www.evokeneuroscience.com) was formed in 2009 with the mission to improve diagnosis and treatment of cognitive disorders with objective, clinically meaningful and easy-to-use products. Primary and specialty care physicians can use eVox® to acquire objective and stable biomarkers of brain function in-office via a non-invasive procedure, in order to aid in the diagnosis of cognitive and mental disorders. Doctors should use their professional judgment in determining when the eVox® System is appropriate to aid in diagnosis.

15 Mar 2019

by Evoke Neuroscience

Evoke Neuroscience to Present at ROTH Capital Conference

Evoke Neuroscience announces it has been selected to present to the attendees of this year’s ROTH Capital...

Evoke Neuroscience announces it has been selected to present to the attendees of this year’s ROTH Capital Conference on March 18 in Orange County, California.

Evoke will present its eVox® System, the FDA-cleared device that aids physicians in the diagnosis of memory loss and other cognitive disorders, to a diverse group of clinicians, investors, and healthcare industry professionals.

Evoke has been recognized for its work to accelerate the eradication of Alzheimer’s disease and other dementias. The eVox System offers doctors the opportunity to implement early interventions to reduce risk of cognitive impairment, Alzheimer’s, and other dementias by aiding doctors in diagnosis of memory loss and other cognitive disorders.

Marinela Gombosev, Chief Executive Officer at Evoke Neuroscience stated, “The eVox System performs a quick, low-cost, and reimbursable procedure to measure brain health and aid in diagnosis. This means an objective evaluation of brain function – once the exclusive domain of a neurologist – is possible in a primary care setting.” And, she explains, “Our technology has the potential to change the standard of care from a cognitive questionnaire to a rapid, objective measurement of brain function – much like a blood pressure cuff is used to measure the heart.”

Historically, most providers have relied on self-report questionnaires and effort-based computerized testing for determining a diagnosis. But to understand the cause of memory loss, it is important to measure key biomarkers of the brain itself. Primary and specialty care physicians can use eVox to acquire these biomarkers, in-office, via a non-invasive procedure performed with minimal staff training and time. Doctors should use their professional judgment in determining when the eVox System is appropriate to aid in diagnosis.   Evoke boasts an impressive portfolio, including an FDA cleared diagnostic device, a Veterans Health Administration FSS contract, well-established insurance reimbursement coding (5 CPT codes), a recently renewed Premier Group Purchase Organization contract, 12 patents awarded (9 Utility, 3 Design), delivery of over 400 eVox Systems to market, and ownership of nearly 50,000 patient brain scans to be used for training AI models.

Marinela Gombosev will present on behalf of Evoke Neuroscience at the ROTH Capital Conference on: Mon, Mar 18 at 9:20-9:40 AM

About ROTH Capital Conference
The 31st ROTH Conference is scheduled for March 17-19, 2019 at the Ritz Carlton, Laguna Niguel, in Orange County, CA. With close to 550 participating companies and over 4,700 attendees, the conference will feature presentations from public and private companies in a variety of sectors. Hosted by ROTH Capital Partners, an investment banking firm dedicated to the small-cap public market, the ROTH Conference has been ranked in the top 100 events in the U.S. for 5 consecutive years.

About Evoke Neuroscience:
Evoke Neuroscience (www.evokeneuroscience.com) was formed in 2009 with the mission to improve diagnosis and treatment of cognitive disorders with objective, clinically meaningful and easy-to-use products. Physicians use the eVox® System to acquire objective and stable biomarkers that may aid in the diagnosis of cognitive diseases such as dementia. Evoke was named one of the INC. 500/5000 fastest growing companies two years in a row.

8 Nov 2018

by Evoke Neuroscience

Evoke Neuroscience awarded People’s Choice Award at OCTANe’s Medical Technology Innovation Forum

NEW YORK, NEW YORK, USA, November 8, 2018 /EINPresswire.com/ – Evoke Neuroscience won the popular vote...

NEW YORK, NEW YORK, USA, November 8, 2018 /EINPresswire.com/ – Evoke Neuroscience won the popular vote by attendees and took home the People’s Choice Award at OCTANe’s 13th Annual Medical Technology Innovation Forum. Recognized for its bold vision of eradicating dementia, Evoke Neuroscience was one of 8 companies selected out of 113 who applied to present via the OCTANe LaunchPad program.

Evoke presented its eVox® System, which aids physicians in the diagnosis of memory loss and other cognitive disorders, to a diverse audience of clinicians, investors, and healthcare industry professionals.

“To date, our eVox System has been used to measure the brain health of over 45,000 patients in primary care clinics and specialty practice settings in the United States.” said Marinela Gombosev, Chief Executive Officer at Evoke Neuroscience. “Our eVox platform helps physicians detect and diagnose memory loss sooner, which means more time for a successful intervention.”

Historically, most providers have relied on self-report questionnaires and effort-based computerized testing for determining a diagnosis. But to understand cognitive health, and more specifically memory, it is important to measure key biomarkers of the brain itself. The eVox® System delivers objective and stable biomarkers that may aid in the diagnosis of cognitive diseases such as dementia.

Primary and specialty care physicians can use eVox® to acquire these biomarkers, in-office, via a non-invasive procedure performed with minimal staff training and time. Doctors should use their professional judgment in determining when the eVox System is appropriate to aid in diagnosis.

About Medical Technology Innovation Forum:
OCTANe’s Medical Technology Innovation Forum (MTIF) is the largest conference in Southern California focused on high-growth medical technology innovation and investment. The collaboration of OCTANe, LaunchPadTM, and the Orange County/Inland Empire SBDC Network has enabled hundreds of life science technology, information technology, sports technology, and clean technology companies to get started and grow. Since 2008, LaunchPad SBDC companies have obtained $1.4 billion of investment capital infusion.

About Evoke Neuroscience:
Evoke Neuroscience (www.evokeneuroscience.com) was formed in 2009 with the mission to improve diagnosis and treatment of cognitive disorders with objective, clinically meaningful and easy-to-use products. Physicians use the eVox® System to acquire objective and stable biomarkers that may aid in the diagnosis of cognitive diseases such as dementia. Evoke was named one of the INC. 500/5000 fastest growing companies two years in a row.

11 Oct 2018

by Evoke Neuroscience

Evoke Neuroscience to present at OCTANe's 13th Annual Medical Technology Innovation Forum

NEW YORK, NY, USA, October 11, 2018 /EINPresswire.com/ – Evoke Neuroscience announces it has been selected...

NEW YORK, NY, USA, October 11, 2018 /EINPresswire.com/ – Evoke Neuroscience announces it has been selected to present to the attendees of this year’s Medical Technology Innovation Forum on October 29th in Newport Beach, California.

Evoke will present its eVox System, which aids physicians in the diagnosis of memory loss and other cognitive disorders, to a diverse group of clinicians, investors and healthcare industry professionals.

Evoke has assembled an executive team of industry veterans and innovators to lead the research, development and commercialization of its next-generation technology.

As of October 4th, 2018, Marinela Gombosev has been promoted to the position of Chief Executive Officer, bringing expertise in medical device operations, product development, marketing and commercialization. Marinela has been EVP of Operations and Marketing at Evoke for four years. Co-founder and Chief Innovation Officer, James Thompson, Ph.D., will continue to ensure that Evoke’s technology is grounded in scientific validity and is maximizing clinical utility for physicians. Peter E. Raymond will lead the company’s next generation research and development as Chief Research and Development Officer. Peter E. Raymond has been named an IBM Global Platinum Entrepreneur for his work in Cognitive Artificial Intelligence (AI), developed the world’s first biometric heart failure simulator, and has been featured by Apple for innovation in healthcare. Co-founder and former Chief Executive Officer, David Hagedorn, Ph.D., will remain on the Evoke Neuroscience Board of Directors.

“To date, our eVox System has been used to measure the brain health of over 45,000 patients in primary care clinics and specialty practice settings in the United States,” said Marinela Gombosev, Chief Executive Officer at Evoke Neuroscience. “Our eVox platform presents a solid foundation for future development to aid doctors in the diagnosis of cognitive diseases such as dementia.”

Historically, most providers have relied on self-report questionnaires and effort-based computerized testing for determining a diagnosis. But to understand cognitive health, and more specifically memory, it is important to measure key biomarkers of the brain itself. The eVox System delivers objective and stable biomarkers that may aid in diagnosis.

Primary and specialty care physicians can use eVox to acquire these biomarkers, in-office, via a non-invasive procedure performed with minimal staff training and time. Doctors should use their professional judgment in determining when the eVox System is appropriate to aid in diagnosis.

About Medical Technology Innovation Forum
OCTANe’s 13th Annual Medical Technology Innovation Forum (MTIF) is the largest conference in Southern California focused on high-growth medical technology innovation and investment. The collaboration of OCTANe, LaunchPadTM, and the Orange County/Inland Empire SBDC Network has enabled hundreds of life science technology, information technology, sports technology, and clean technology companies to get started and grow. Since 2008, LaunchPad SBDC companies have obtained $1.4 billion of investment capital infusion.

About Evoke Neuroscience
Evoke Neuroscience (www.evokeneuroscience.com) was formed in 2009 with the mission to improve diagnosis and treatment of cognitive disorders with objective, clinically meaningful and easy-to-use products. Physicians use the eVox System to acquire objective and stable biomarkers that may aid in the diagnosis of cognitive diseases such as dementia. Evoke was named one of the INC. 500/5000 fastest growing companies two years in a row.

29 Mar 2018

by Evoke Neuroscience

Evoke Neuroscience awarded Breakthrough Technology agreement with Premier

New York, NY, March 29, 2018 – Evoke Neuroscience has been awarded a group purchasing agreement as...

New York, NY, March 29, 2018 – Evoke Neuroscience has been awarded a group purchasing agreement as a breakthrough technology with Premier. Effective March 1, 2018, the agreement allows Premier members to take advantage of special pricing and terms pre-negotiated by Premier for the eVox^® System, the medical device that assesses brain function to aid doctors in the diagnosis of cognitive disorders.

“We are thrilled to be recognized by Premier as a Breakthrough Technology,” said John Armstrong, Executive Vice President of Sales at Evoke Neuroscience. “This Technology Breakthroughs contract recognizes the innovative way that the eVox System aids primary care physicians in their diagnosis of patients with memory loss and other cognitive disorders.”

Historically, most providers have relied on self-report questionnaires and effort-based computerized testing for determining a diagnosis. But to understand cognitive health, and more specifically memory, it is important to measure key biomarkers of the brain itself. The eVox^® System fulfills the need for objective memory-related biomarkers that aid in the diagnosis of cognitive diseases such as dementia.

Primary and specialty care physicians can use eVox^® to acquire these biomarkers in-house via a non-invasive procedure performed with minimal staff training and time. Doctors should use their professional judgment in determining when the eVox^® System is appropriate to aid in diagnosis.

Premier is a leading healthcare improvement company, uniting an alliance of approximately 3,900 U.S. hospitals and 150,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.

About Evoke Neuroscience

Evoke Neuroscience (www.evokeneuroscience.com) was formed in 2009 with the mission to improve diagnosis and treatment of cognitive disorders with objective, clinically meaningful and easy-to-use products. Physicians use the eVox^® System to assess brain health and aid in the diagnosis of memory loss and other cognitive disorders.

5 Feb 2018

by Evoke Neuroscience

Evoke Neuroscience announces award of VA contract for the eVox® System

Evoke Neuroscience, Inc. is pleased to announce the award of a Veterans Health Administration Contract...

Evoke Neuroscience, Inc. is pleased to announce the award of a Veterans Health Administration Contract for the eVox® System. The Contract award #36F79718D0348 enables the VA and other federal organizations to purchase the eVox System at pre-approved pricing via the Veterans Administration’s FSS Contract, via GSA Advantage, or GSA eBUY.

The eVox System measures brain health to aid doctors in the diagnosis of cognitive disorders. By measuring brain function directly, physicians can enhance their clinical work-up beyond standard subjective patient questionnaires. eVox provides clinically actionable and objective biomarkers of brain health pertinent to conditions like Alzheimer’s disease, mild cognitive impairment, and other cognitive disorders.

Evoke has a long history in supporting military personnel and veterans with their cognitive health needs. The company was borne out of work done to treat PTSD and TBI at the Marine Corps Base in Camp Lejeune nearly 10 years ago. “With this FSS contract, we can now deliver our technology to more of those who have served,” explained Evoke Neuroscience CEO David Hagedorn, Ph.D. “We strive to improve the diagnosis and treatment of brain disorders for patients throughout the country – and veterans are among those who need us most. We are exceptionally proud to offer our eVox System to the Veterans Administration Health System and the U.S. Military Health System.”

About Evoke Neuroscience, Inc.

Evoke Neuroscience (www.evokeneuroscience.com) was formed in 2009 with the mission to improve diagnosis and treatment of cognitive disorders with objective, clinically meaningful and easy-to-use products. Physicians use the eVox® System to assess brain health and aid in the diagnosis of memory loss and other cognitive disorders.

15 May 2017

by Evoke Neuroscience

The Silicon Review

The Silicon Review – May 15, 2017 Evoke Neuroscience named as one of 50 most valuable brands of the...

The Silicon Review – May 15, 2017
Evoke Neuroscience named as one of 50 most valuable brands of the year 2017.

Catch up on the latest from Evoke

References

Contact Us